drugset

drugset / Trial / NCT00628108

Safety Study of Levocetirizine Dihydrochloride Oral Liquid Formulation in Children Aged 6 Months to 11 Months

NCT00628108 ↗

Phase 3 Completed 69 enrolled UCB Pharma

RandomizedParallel-groupTriple-blindTreatment

Summary

To determine the safety of levocetirizine in children ages 6-11 months with symptoms of allergic rhinitis or chronic idiopathic urticaria.

Timeline

Start: 2008-03
Primary completion: 2008-09
Completion: 2008-09

Publications

Hampel F, Ratner P, Haeusler JM. Safety and tolerability of levocetirizine dihydrochloride in infants and children with allergic rhinitis or chronic urticaria. Allergy Asthma Proc. 2010 Jul-Aug;31(4):290-5. doi: 10.2500/aap.2010.31.3349.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Levocetirizine	Unknown	1.25 mg	Oral

Indications